Keyword: Kevzara (sarilumab)
Sanofi's CFO search lasted two months and led the company to a financial executive from French automaker PSA Group.
Sanofi's net prices fell 8.4% last year, the drugmaker reported in an update to its pricing policies.
Regeneron needs some Type A newcomers to backstop its aging blockbuster Eylea, but so far, its trio of launches are still seeking traction.
Sanofi and Regeneron may have had a successful year with Dupixent—approved in March to treat atopic dermatitis—but there's much more to come.
Could Dupixent end up beating Novartis’ Cosentyx on launch trajectory? The numbers are looking that way so far, a Sanofi executive said Monday.
Eli Lilly’s RA med baricitinib had been pegged as one of 2017’s hottest launches—and a threat to Pfizer’s Xeljanz. Not anymore.
Eli Lilly has won a nod from NICE for its anticipated blockbuster and Humira competitor, Olumiant, a drug the FDA rejected in April.
Halfway into 2017, the FDA has beaten last year's drug-approvals tally with a crop featuring controversy, sales firepower and one very high price.
With biologics dominating its pipeline, Sanofi will spend as much as $2 billion on its biologics manufacturing network over the next several years.